---
title: "Zhejiang ALK received the \"Drug Registration Certificate\" for Amlodipine Besylate Tablets from the U.S"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260856536.md"
description: "Zhejiang ALK Pharmaceutical Co., Ltd. recently obtained the \"Drug Registration Certificate\" for Amlodipine Besylate Tablets issued by the National Medical Products Administration. This medication is used for the treatment of adult primary hypertension, with specifications of 40mg and 80mg, and the approval number is valid until September 29, 2030. This approval is considered equivalent to passing the consistency evaluation, which will enrich the company's product pipeline. However, due to the particularity of the pharmaceutical industry, drug sales are influenced by policy and market factors, and the specific sales situation is uncertain. The company reminds investors to pay attention to risks"
datetime: "2025-10-13T08:40:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260856536.md)
  - [en](https://longbridge.com/en/news/260856536.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260856536.md)
generator: "portal-rs"
---

# Zhejiang ALK received the "Drug Registration Certificate" for Amlodipine Besylate Tablets from the U.S

Recently, Zhejiang ALK Pharmaceuticals Co., Ltd. received the "Drug Registration Certificate" for Measartan Potassium Tablets issued by the National Medical Products Administration. The generic name of this drug is Measartan Potassium Tablets, with main ingredient Measartan Potassium, available in two specifications: 40mg and 80mg. The approval number is valid until September 29, 2030. Measartan Potassium Tablets can be used to treat primary hypertension in adults, and the company received the acceptance notice in 2024. This approval is considered equivalent to passing the consistency evaluation, which will enrich the company's product pipeline. However, due to the particularity of the pharmaceutical industry, drug sales are affected by policies, market conditions, and other factors, making the specific sales situation uncertain. The company reminds investors to pay attention to risks

### Related Stocks

- [002940.CN](https://longbridge.com/en/quote/002940.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Frozen blueberries recall categorized under FDA's highest Class I risk level](https://longbridge.com/en/news/296506599.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)
- [The world’s biggest EV battery maker says all 20 plants are carbon neutral](https://longbridge.com/en/news/296132594.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**